Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharming Group N.V (PHAR) Operating Expenses: 2020-2025

Historic Operating Expenses for Pharming Group N.V (PHAR) over the last 4 years, with Jun 2025 value amounting to -$87.8 million.

  • Pharming Group N.V's Operating Expenses fell 24.01% to -$87.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $66.0 million, marking a year-over-year decrease of 15.25%. This contributed to the annual value of $153.8 million for FY2024, which is 23.24% up from last year.
  • As of Q2 2025, Pharming Group N.V's Operating Expenses stood at -$87.8 million, which was down 133.70% from $260.6 million recorded in Q4 2024.
  • In the past 5 years, Pharming Group N.V's Operating Expenses ranged from a high of $260.6 million in Q4 2024 and a low of -$87.8 million during Q2 2025.
  • For the 3-year period, Pharming Group N.V's Operating Expenses averaged around $14.6 million, with its median value being -$33.6 million (2024).
  • As far as peak fluctuations go, Pharming Group N.V's Operating Expenses skyrocketed by 365.82% in 2021, and later plummeted by 126,382.28% in 2022.
  • Quarterly analysis of 5 years shows Pharming Group N.V's Operating Expenses stood at $107.4 million in 2021, then spiked by 56.96% to $168.6 million in 2022, then rose by 26.86% to $213.9 million in 2023, then rose by 21.83% to $260.6 million in 2024, then declined by 24.01% to -$87.8 million in 2025.
  • Its Operating Expenses stands at -$87.8 million for Q2 2025, versus $260.6 million for Q4 2024 and -$36.0 million for Q3 2024.